Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants.
We hypothesized that abnormal fetal lung growth in experimental congenital diaphragmatic hernia after maternal nitrofen exposure alters lung structure due to impaired VEGF signaling, which can be reversed with VEGF or nitric oxide (NO) treatment. Timed-pregnant Sprague-Dawley rats were treated with nitrofen on embryonic day 9 (E9), and fetal lungs were harvested for explant culture on E15. Explants were maintained in 3% O2 for 3 days and were treated with NO gas or recombinant human VEGF protein for 3 days. To determine the effects of VEGF inhibition on lung structure, normal fetal lung explants were treated with SU-5416, a VEGF receptor inhibitor, with or without exogenous NO or VEGF. We found that nitrofen treatment impaired lung structure, as evidenced by decreased branching at day 0, but lung structure was not different from controls after 3 days in culture. Nitrofen reduced lung VEGF but not endothelial NO synthase protein level. Treatment with NO enhanced lung growth in control and nitrofen-exposed lungs; however, the response to NO in the nitrofen-treated lungs was reduced when compared with controls. VEGF treatment did not cause a further increase in lung complexity after nitrofen exposure. SU-5416 treatment altered lung structure, which improved with NO but not VEGF treatment. Both nitrofen and SU-5416 treatment increased apoptosis in the mesenchyme of fetal lung explants. We conclude that nitrofen exposure increased apoptosis, decreased lung growth and reduced VEGF expression, and that exogenous NO but not VEGF treatment enhances lung growth. Disruption of lung architecture after VEGF receptor blockade was similar to nitrofen-induced changes but was more responsive to NO.
Muehlethaler
Vincent
V
Pediatric Heart Lung Center, Dept. of Pediatrics, Univ. of Colorado School of Medicine and The Children's Hospital, Mail Stop 8317, PO Box 6511, Aurora, CO 80045' USA. Vincent.Muehlethaler@mac.com
Kunig
Anette M
AM
Seedorf
Gregory
G
Balasubramaniam
Vivek
V
Abman
Steven H
SH
D000818:Animals; D005333:Fetus; D007211:Indoles / Q000494:pharmacology; D008168:Lung / Q000187:drug effects / Q000196:embryology*; D023421:Models, Animal; D009569:Nitric Oxide / Q000502:physiology*; D010647:Phenyl Ethers / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
D007211:Indoles; D010647:Phenyl Ethers; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D009569:Nitric Oxide; C116890:Semaxinib; D040262:Receptors, Vascular Endothelial Growth Factor; C007350:nitrofen